NCT02070549: Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Symptomatic or untreated leptomeningeal or brain metastases

Comments are closed.

Up ↑